Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 81338
1. Sommer I, Griebler U, Kien C, Auer S, Klerings I, Hammer R, Holzer P, Gartlehner G: Vitamin D deficiency as a risk factor for dementia: a systematic review and meta-analysis. BMC Geriatr; 2017 Jan 13;17(1):16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin D deficiency as a risk factor for dementia: a systematic review and meta-analysis.
  • BACKGROUND: Sunlight exposure and high vitamin D status have been hypothesised to reduce the risk of developing dementia.
  • The objective of our research was to determine whether lack of sunlight and hypovitaminosis D over time are associated with dementia.
  • We conducted random effects meta-analyses of published and unpublished data to evaluate the influence of sunlight exposure or vitamin D as a surrogate marker on dementia risk.
  • RESULTS: We could not identify a single study investigating the association between sunlight exposure and dementia risk.
  • Six cohort studies provided data on the effect of serum vitamin D concentration on dementia risk.
  • The strength of evidence that serious vitamin D deficiency increases the risk of developing dementia, however, is very low due to the observational nature of included studies and their lack of adjustment for residual or important confounders (e.g.
  • ApoE ε4 genotype), as well as the indirect relationship between Vitamin D concentrations as a surrogate for sunlight exposure and dementia risk.
  • CONCLUSIONS: The results of this systematic review show that low vitamin D levels might contribute to the development of dementia.
  • Further research examining the direct and indirect relationship between sunlight exposure and dementia risk is needed.
  • Such research should involve large-scale cohort studies with homogeneous and repeated assessment of vitamin D concentrations or sunlight exposure and dementia outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28086755.001).
  • [ISSN] 1471-2318
  • [Journal-full-title] BMC geriatrics
  • [ISO-abbreviation] BMC Geriatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Dementia / Meta-analysis / Systematic review / Vitamin D
  •  go-up   go-down


2. Wang CN, Wang YJ, Wang H, Song L, Chen Y, Wang JL, Ye Y, Jiang B: The Anti-dementia Effects of Donepezil Involve miR-206-3p in the Hippocampus and Cortex. Biol Pharm Bull; 2017 Apr 01;40(4):465-472

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Anti-dementia Effects of Donepezil Involve miR-206-3p in the Hippocampus and Cortex.
  • Alzheimer's disease (AD) is a most serious age-related neurodegenerative disorder accompanied with significant memory impairments in this world.
  • In addition, enhancing the miR-206-3p level by the usage of AgomiR-206-3p significantly attenuated the anti-dementia effects of donepezil in APP/PS1 mice.
  • Together, these results suggested that miR-206-3p is involved in the anti-dementia effects of donepezil, and could be a novel pharmacological target for treating AD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28123152.001).
  • [ISSN] 1347-5215
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Karkou V, Meekums B: Dance movement therapy for dementia. Cochrane Database Syst Rev; 2017 Feb 03;2:CD011022
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dance movement therapy for dementia.
  • BACKGROUND: Dementia is a collective name for different degenerative brain syndromes which, according to Alzheimer's Disease International, affects approximately 35.6 million people worldwide.
  • The latest NICE guideline for dementia highlights the value of diverse treatment options for the different stages and symptoms of dementia including non-pharmacological treatments.
  • Dance movement therapy is an embodied psychological intervention that can address complexity and thus, may be useful for people with dementia, but its effectiveness remains unclear.
  • OBJECTIVES: To assess the effects of dance movement therapy on behavioural, social, cognitive and emotional symptoms of people with dementia in comparison to no treatment, standard care or any other treatment.
  • SEARCH METHODS: Searches took place up to March 2016 through ALOIS, Cochrane Dementia and Cognitive Improvement's Specialized Register, which covers CENTRAL, a number of major healthcare databases and trial registers, and grey literature sources.
  • Studies considered had to include people with dementia, in any age group and in any setting, with interventions delivered by a dance movement therapy practitioner who (i) had received formal training (ii) was a dance movement therapist in training or (iii) was otherwise recognised as a dance movement therapist in the country in which the study was conducted.
  • AUTHORS' CONCLUSIONS: Trials of high methodological quality, large sample sizes and clarity in the way the intervention is put together and delivered are needed to assess whether dance movement therapy is an effective intervention for dementia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28155990.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


5. Lou J, Teng Z, Zhang L, Yang J, Ma L, Wang F, Tian X, An R, Yang M, Zhang Q, Xu L, Dong Z: β-Caryophyllene/Hydroxypropyl-β-Cyclodextrin Inclusion Complex Improves Cognitive Deficits in Rats with Vascular Dementia through the Cannabinoid Receptor Type 2 -Mediated Pathway. Front Pharmacol; 2017;8:2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] β-Caryophyllene/Hydroxypropyl-β-Cyclodextrin Inclusion Complex Improves Cognitive Deficits in Rats with Vascular Dementia through the Cannabinoid Receptor Type 2 -Mediated Pathway.
  • : This work was conducted to prepare β-caryophyllene-hydroxypropyl-β-cyclodextrin inclusion complex (HPβCD/BCP) and investigate its effects and mechanisms on cognitive deficits in vascular dementia (VD) rats.
  • HPβCD/BCP and AM630 were then administered to VD rats to upregulate and downregulate the cannabinoid receptor type 2 (CB2).
  • Overall, the findings demonstrated the protective effects of HPβCD/BCP against cognitive deficits induced by chronic cerebral ischemia and suggested the potential of HPβCD/BCP in the therapy of vascular dementia in the future.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28154534.001).
  • [Journal-full-title] Frontiers in pharmacology
  • [ISO-abbreviation] Front Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; CB2 / hydroxypropyl-β-cyclodextrin / inclusion complex / vascular dementia / β-caryophyllene
  •  go-up   go-down


6. Smith D, Lovell J, Weller C, Kennedy B, Winbolt M, Young C, Ibrahim J: A systematic review of medication non-adherence in persons with dementia or cognitive impairment. PLoS One; 2017;12(2):e0170651
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic review of medication non-adherence in persons with dementia or cognitive impairment.
  • BACKGROUND: Adherence to medication is vital for disease management while simultaneously reducing healthcare expenditure.
  • METHODS: A seven database systematic search of studies published between 1 January 1949-31 December 2015 examining medication non-adherence in community dwelling persons with CI or dementia was conducted.
  • Articles reporting medication non-adherence in people with CI or dementia in the community, with or without caregiver supports were eligible for inclusion.
  • Papers reporting adherence to treatments in cognitively intact populations, populations from hospital or institutional settings, for non-prescribed medication or those describing dementia as a factor predicting medication non-adherence were excluded.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Psychol Aging. 1992 Jun;7(2):252-6 [1610514.001]
  • [Cites] Telemed J E Health. 2009 Oct;15(8):770-6 [19780692.001]
  • [Cites] J Gerontol B Psychol Sci Soc Sci. 2006 Mar;61(2):P102-7 [16497953.001]
  • [Cites] Circulation. 2009 Jun 16;119(23):3028-35 [19528344.001]
  • [Cites] Scand J Prim Health Care. 1989 Oct;7(3):179-80 [2587874.001]
  • [Cites] Eur J Cardiovasc Nurs. 2003 Sep;2(3):219-28 [14622630.001]
  • [Cites] Heart Lung. 2012 Nov-Dec;41(6):572-82 [22784869.001]
  • [Cites] Ann Behav Med. 2003 Aug;26(1):1-7 [12867348.001]
  • [Cites] Drugs Aging. 2008;25(12):1033-47 [19021302.001]
  • [Cites] BMC Med. 2014 Oct 31;12:192 [25358236.001]
  • [Cites] Int J Geriatr Psychiatry. 2007 Jan;22(1):55-60 [17006873.001]
  • [Cites] J Gerontol Nurs. 1994 Jul;20(7):41-7 [8046218.001]
  • [Cites] Health Psychol. 2010 Jan;29(1):50-5 [20063935.001]
  • [Cites] J Clin Epidemiol. 2001 Dec;54 Suppl 1:S57-60 [11750211.001]
  • [Cites] BMJ. 2009 Jul 21;339:b2700 [19622552.001]
  • [Cites] Curr Clin Pharmacol. 2015;10(3):213-21 [26265487.001]
  • [Cites] Am J Alzheimers Dis Other Demen. 2012 Jun;27(4):238-42 [22739031.001]
  • [Cites] Aging Clin Exp Res. 2012 Dec;24(6):718-21 [22732397.001]
  • [Cites] Ann Pharmacother. 2009 Feb;43(2):185-93 [19193586.001]
  • [Cites] Cancer Prev Res (Phila). 2014 Jan;7(1):161-8 [24253314.001]
  • [Cites] Am J Geriatr Pharmacother. 2012 Jun;10(3):165-77 [22657941.001]
  • [Cites] J Health Serv Res Policy. 2005 Jul;10 Suppl 1:21-34 [16053581.001]
  • [Cites] Neuropsychology. 2015 Nov;29(6):919-25 [25730729.001]
  • [Cites] Drugs Aging. 2004;21(12):793-811 [15382959.001]
  • [Cites] Am J Geriatr Pharmacother. 2008 Dec;6(5):255-63 [19161928.001]
  • [Cites] Am J Health Promot. 2010 Nov-Dec;25(2):126-33 [21039294.001]
  • [Cites] Appl Neuropsychol. 2002;9(3):187-91 [12584085.001]
  • [Cites] Int J Geriatr Psychiatry. 1997 Sep;12(9):920-5 [9309470.001]
  • [Cites] PLoS One. 2015 Dec 16;10(12):e0145076 [26674526.001]
  • [Cites] J Am Geriatr Soc. 1996 Jul;44(7):828-31 [8675933.001]
  • [Cites] J Nurs Scholarsh. 2003;35(3):207 [14562485.001]
  • [Cites] J Gerontol Soc Work. 2006;47(3-4):31-46 [17062521.001]
  • [Cites] J Gen Intern Med. 2005 Jul;20(7):572-7 [16050849.001]
  • [Cites] Am J Alzheimers Dis Other Demen. 2007 Feb-Mar;22(1):20-6 [17533998.001]
  • [Cites] Eur J Heart Fail. 2010 May;12(5):508-15 [20354031.001]
  • [Cites] Int J Geriatr Psychiatry. 2012 Dec;27(12):1275-82 [22337284.001]
  • [Cites] J Clin Pharm Ther. 2001 Oct;26(5):331-42 [11679023.001]
  • [Cites] Cochrane Database Syst Rev. 2014 Nov 20;(11):CD000011 [25412402.001]
  • [Cites] J Psychiatr Pract. 2009 Jan;15(1):34-44 [19182563.001]
  • [Cites] Clin Infect Dis. 2005 Sep 15;41(6):875-82 [16107989.001]
  • [Cites] Eur J Clin Pharmacol. 2001 Oct;57(8):589-94 [11758637.001]
  • [Cites] AIDS Behav. 2011 Nov;15(8):1888-94 [21437726.001]
  • (PMID = 28166234.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Yu H, Chen T, Zhou L, Tang J: Effect of Selective 5-HT6R Agonist on Expression of 5-HT Receptor and Neurotransmitter in Vascular Dementia Rats. Med Sci Monit; 2017 Feb 15;23:818-825

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Selective 5-HT6R Agonist on Expression of 5-HT Receptor and Neurotransmitter in Vascular Dementia Rats.
  • However, whether 5-HT6R is involved in the development of vascular dementia (VD) remains unclear.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28196966.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Farina N, Llewellyn D, Isaac MG, Tabet N: Vitamin E for Alzheimer's dementia and mild cognitive impairment. Cochrane Database Syst Rev; 2017 01 27;1:CD002854
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin E for Alzheimer's dementia and mild cognitive impairment.
  • Evidence that free radicals may contribute to the pathological processes behind cognitive impairment has led to interest in the use of vitamin E supplements to treat mild cognitive impairment (MCI) and Alzheimer's disease (AD).
  • OBJECTIVES: To assess the efficacy of vitamin E in the treatment of MCI and dementia due to AD.
  • SEARCH METHODS: We searched the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (ALOIS), the Cochrane Library, MEDLINE, Embase, PsycINFO, CINAHL, LILACS as well as many trials databases and grey literature sources on 22 April 2016 using the terms: "Vitamin E", vitamin-E, alpha-tocopherol.
  • It was not possible to pool data across studies owing to a lack of comparable outcome measures.In people with AD, we found no evidence of any clinically important effect of vitamin E on cognition, measured with change from baseline in the Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog) over six to 48 months (mean difference (MD) -1.81, 95% confidence interval (CI) -3.75 to 0.13, P = 0.07, 1 study, n = 272; moderate quality evidence).
  • People with AD receiving vitamin E showed less functional decline on the Alzheimer's Disease Cooperative Study/Activities of Daily Living Inventory than people receiving placebo at six to 48 months (mean difference (MD) 3.15, 95% CI 0.07 to 6.23, P = 0.04, 1 study, n = 280; moderate quality evidence).
  • There was no evidence of any clinically important effect on neuropsychiatric symptoms measured with the Neuropsychiatric Inventory (MD -1.47, 95% CI -4.26 to 1.32, P = 0.30, 1 study, n = 280; moderate quality evidence).We found no evidence that vitamin E affected the probability of progression from MCI to probable dementia due to AD over 36 months (RR 1.03, 95% CI 0.79 to 1.35, P = 0.81, 1 study, n = 516; moderate quality evidence).
  • AUTHORS' CONCLUSIONS: We found no evidence that the alpha-tocopherol form of vitamin E given to people with MCI prevents progression to dementia, or that it improves cognitive function in people with MCI or dementia due to AD.
  • [MeSH-major] Alzheimer Disease / drug therapy. Antioxidants / therapeutic use. Cognitive Dysfunction / drug therapy. Vitamin E / therapeutic use
  • [MeSH-minor] Disease Progression. Humans. Outcome Assessment (Health Care). Randomized Controlled Trials as Topic. alpha-Tocopherol / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateOf] Cochrane Database Syst Rev. 2012 Nov 14;11:CD002854 [23152215.001]
  • (PMID = 28128435.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 1406-18-4 / Vitamin E; H4N855PNZ1 / alpha-Tocopherol
  •  go-up   go-down


9. Müller P, Schmicker M, Müller NG: [Preventive strategies for dementia]. Z Gerontol Geriatr; 2017 May;50(Suppl 2):89-95

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preventive strategies for dementia].
  • [Transliterated title] Präventionsstrategien gegen Demenz.
  • In the context of the demographically induced increase in the prevalence of dementia and the simultaneous lack of causal pharmacological therapies, preventive approaches are gaining in importance.
  • This article summarizes the current developments in preventing dementia by modification of life style factors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28243736.001).
  • [ISSN] 1435-1269
  • [Journal-full-title] Zeitschrift fur Gerontologie und Geriatrie
  • [ISO-abbreviation] Z Gerontol Geriatr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Aging / Alzheimer disease / Dancing / Neuroplasticity / Physical exercise
  •  go-up   go-down


10. Kirkham J, Sherman C, Velkers C, Maxwell C, Gill S, Rochon P, Seitz D: Antipsychotic Use in Dementia. Can J Psychiatry; 2017 Mar;62(3):170-181

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antipsychotic Use in Dementia.
  • Current controversy exists over the role of antipsychotics in the management of neuropsychiatric symptoms (NPS) in persons with dementia.
  • Approximately one-third of all persons with dementia are currently prescribed antipsychotic medications, and there is significant variation in the use of antipsychotics across care settings and providers.
  • Reducing the inappropriate or unnecessary use of antipsychotics among persons with dementia has been the focus of increasing attention owing to better awareness of the potential problems associated with these medications.
  • Several approaches can be used to curb the use of antipsychotics among persons with dementia, including policy or regulatory changes, public reporting, and educational outreach.
  • Although reducing the inappropriate use of antipsychotics is a complex task, psychiatrists can play an important role via the provision of clinical care and research evidence, contributing to improved care of persons with dementia in Canada and elsewhere.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Psychogeriatr. 2009 Jun;21(3):485-93 [19368752.001]
  • [Cites] J Am Geriatr Soc. 1997 Aug;45(8):977-85 [9256852.001]
  • [Cites] Am J Psychiatry. 2011 Aug;168(8):831-9 [21572163.001]
  • [Cites] J Am Med Dir Assoc. 2014 Oct;15(10):706-18 [25112229.001]
  • [Cites] Int J Geriatr Psychiatry. 2010 Sep;25(9):917-22 [20803721.001]
  • [Cites] J Aging Health. 1991 Nov;3(4):455-72 [10115034.001]
  • [Cites] Arch Intern Med. 2007 Apr 9;167(7):676-83 [17420426.001]
  • [Cites] Am J Geriatr Psychiatry. 2015 Dec;23(12):1259-69 [26525997.001]
  • [Cites] Am J Psychiatry. 2016 May 1;173(5):543-6 [27133416.001]
  • [Cites] Can Geriatr J. 2012 Dec;15(4):120-6 [23259025.001]
  • [Cites] Arch Intern Med. 2010 Jan 11;170(1):89-95 [20065204.001]
  • [Cites] Am J Geriatr Psychiatry. 2006 Mar;14 (3):191-210 [16505124.001]
  • [Cites] J Palliat Med. 2013 Jan;16(1):31-7 [23234299.001]
  • [Cites] Int J Geriatr Psychiatry. 2001 Jan;16(1):39-44 [11180484.001]
  • [Cites] Clin Drug Investig. 2010;30(1):63-70 [19995099.001]
  • [Cites] Int J Geriatr Psychiatry. 1997 May;12(5):533-6 [9193961.001]
  • [Cites] JAMA. 2005 Oct 19;294(15):1934-43 [16234500.001]
  • [Cites] Psychiatr Serv. 1997 Oct;48(10):1289-96 [9323748.001]
  • [Cites] Cochrane Database Syst Rev. 2012 Jun 13;(6):CD000259 [22696318.001]
  • [Cites] Lancet Neurol. 2009 Feb;8(2):151-7 [19138567.001]
  • [Cites] Cochrane Database Syst Rev. 2013 Mar 28;(3):CD007726 [23543555.001]
  • [Cites] Med Care. 2003 Jan;41(1 Suppl):I30-8 [12544814.001]
  • [Cites] Med Care. 2009 Sep;47(9):1000-8 [19648835.001]
  • [Cites] Health Serv Res. 2015 Aug;50(4):1069-87 [25600861.001]
  • [Cites] Drugs Aging. 2013 Jul;30(7):569-85 [23605786.001]
  • [Cites] Drugs Aging. 2012 Sep;29(9):759-69 [23018612.001]
  • [Cites] Psychiatr Serv. 1998 Feb;49(2):229-33 [9575011.001]
  • [Cites] Int Psychogeriatr. 2004 Dec;16(4):461-80 [15715361.001]
  • [Cites] JAMA. 1988 Nov 25;260(20):3016-20 [2903260.001]
  • [Cites] N Engl J Med. 2012 Oct 18;367(16):1497-507 [23075176.001]
  • [Cites] J Am Med Dir Assoc. 2012 Jul;13(6):503-506.e2 [22342481.001]
  • [Cites] Arch Intern Med. 2008 May 26;168(10):1090-6 [18504337.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2008 Sep;17(9):912-8 [18398935.001]
  • [Cites] CNS Drugs. 2005;19(2):91-103 [15697324.001]
  • [Cites] Am J Psychiatry. 1992 Oct;149(10):1390-2 [1530076.001]
  • [Cites] Int J Geriatr Psychiatry. 2007 Jul;22(7):632-8 [17136713.001]
  • [Cites] Int Psychogeriatr. 2011 Dec;23(10):1632-9 [21813036.001]
  • [Cites] J Am Med Dir Assoc. 2011 Nov;12(9):648-54 [21450189.001]
  • [Cites] Int J Geriatr Psychiatry. 2002 May;17(5):403-8 [11994927.001]
  • [Cites] Eur Neuropsychopharmacol. 2013 Sep;23(9):1034-42 [23498307.001]
  • [Cites] Eur Neuropsychopharmacol. 2014 Jan;24(1):95-104 [24126116.001]
  • [Cites] Int Psychogeriatr. 2004 Mar;16(1):61-74 [15190997.001]
  • [Cites] Am J Psychiatry. 2016 Mar 1;173(3):252-62 [26585409.001]
  • [Cites] Am J Geriatr Psychiatry. 2007 May;15(5):416-24 [17463191.001]
  • [Cites] Ann Intern Med. 2008 Jan 15;148(2):111-23 [18195336.001]
  • [Cites] Int Psychogeriatr. 2010 Feb;22(1):120-8 [19735591.001]
  • [Cites] J Am Geriatr Soc. 2006 Jan;54(1):104-9 [16420205.001]
  • [Cites] CMAJ. 2008 Aug 26;179(5):438-46 [18725616.001]
  • [Cites] J Am Geriatr Soc. 2016 Feb;64(2):299-305 [26889839.001]
  • [Cites] Int Psychogeriatr. 2006 Dec;18(4):713-26 [16879762.001]
  • [Cites] JAMA. 1994 Feb 2;271(5):358-62 [8283585.001]
  • [Cites] JAMA. 2002 Sep 25;288(12):1475-83 [12243634.001]
  • [Cites] Alzheimers Dement. 2012 Sep;8(5):453-7 [22285636.001]
  • [Cites] Br J Psychiatry. 2012 Sep;201(3):221-6 [22790679.001]
  • [Cites] Nurs Res. 2006 Jul-Aug;55(4):252-8 [16849977.001]
  • [Cites] Arch Gen Psychiatry. 2011 Feb;68(2):190-7 [21300946.001]
  • [Cites] Drugs Aging. 2005;22(9):793-800 [16156683.001]
  • [Cites] J Am Geriatr Soc. 2009 Dec;57(12):2269-74 [19874411.001]
  • [Cites] J Health Polit Policy Law. 2006 Aug;31(4):773-810 [16971545.001]
  • [Cites] J Geriatr Psychiatry Neurol. 2007 Jun;20(2):100-6 [17548780.001]
  • [Cites] Hum Psychopharmacol. 2011 Jan;26(1):12-20 [21394786.001]
  • [Cites] BMJ. 2011 Jun 21;342:d3514 [21693525.001]
  • [Cites] Int Psychogeriatr. 2001 Mar;13(1):93-106 [11352339.001]
  • [Cites] JAMA. 2013 Feb 6;309(5):440-2 [23385262.001]
  • [Cites] J Am Geriatr Soc. 2011 Nov;59(11):2100-7 [22092099.001]
  • [Cites] Int Psychogeriatr. 2011 Oct;23(8):1240-8 [21418723.001]
  • [Cites] Am J Public Health. 1995 Jun;85(6):771-6 [7762708.001]
  • [Cites] Int Clin Psychopharmacol. 2009 Mar;24(2):97-104 [21456106.001]
  • [Cites] Health Aff (Millwood). 2009 Sep-Oct;28(5):w770-81 [19622537.001]
  • [Cites] Int J Psychiatry Med. 2010;40(4):425-38 [21391413.001]
  • [Cites] Int J Geriatr Psychiatry. 2007 Sep;22(9):843-9 [17193341.001]
  • [Cites] J Am Geriatr Soc. 2014 Mar;62(3):454-61 [24617991.001]
  • [Cites] Age Ageing. 2006 Sep;35(5):508-13 [16807310.001]
  • [Cites] Am J Psychiatry. 2008 Jul;165(7):844-54 [18519523.001]
  • [Cites] Drugs Aging. 2009;26(6):483-92 [19591523.001]
  • [Cites] Am J Public Health. 1980 May;70(5):485-91 [6103676.001]
  • [Cites] Int J Geriatr Psychiatry. 2010 Feb;25(2):160-5 [19513989.001]
  • [Cites] Int Psychogeriatr. 2012 Jun;24(6):940-7 [22333005.001]
  • [Cites] Age Ageing. 2011 May;40(3):368-75 [21429950.001]
  • [Cites] Pharmacotherapy. 1995 Jul-Aug;15(4):495-501 [7479203.001]
  • [Cites] Dtsch Arztebl Int. 2010 May;107(18):320-7 [20517530.001]
  • [Cites] Psychiatr Serv. 1996 Sep;47(9):951-5 [8875659.001]
  • [Cites] Int J Geriatr Psychiatry. 2003 Dec;18(12):1135-41 [14677146.001]
  • [Cites] BMJ. 2015 Mar 02;350:h369 [25731881.001]
  • [Cites] Med Care. 2014 Mar;52(3):267-71 [24374410.001]
  • [Cites] Int Psychogeriatr. 2013 Sep;25(9):1415-23 [23782794.001]
  • [Cites] Prim Care Companion J Clin Psychiatry. 2008;10(2):97-102 [18458729.001]
  • [Cites] Drugs Aging. 2005;22(4):339-51 [15839722.001]
  • [Cites] Int Psychogeriatr. 2014 Mar;26(3):363-71 [24252349.001]
  • [Cites] BMJ Open. 2013 Jan 07;3(1):null [23299113.001]
  • [Cites] JAMA. 2000 Apr 12;283(14 ):1866-74 [10770149.001]
  • (PMID = 28212496.001).
  • [ISSN] 1497-0015
  • [Journal-full-title] Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • [ISO-abbreviation] Can J Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; adverse events / antipsychotics / dementia / long-term care / quality improvement / quality of care
  •  go-up   go-down






Advertisement